The Challenges of Developing Aging Biomarkers


Old man walking on a clockOld man walking on a clock

A new study reviews the state of the art of aging biomarkers and explores the future development of even better ways of measuring biological age.

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

The need for better aging biomarkers

Human life expectancy has been increasing throughout the 20th and 21st centuries due to improvements such as better access to healthcare and sanitation, lower child mortality, reduction of poverty, and better education access.

This steady increase in life expectancy results in a larger population of older people. However, with that increase also comes a rising prevalence of age-related diseases and disabilities. Current medicine does a great job at keeping people alive for longer, but that extra time does not always come with accompanying good health or quality of life.

It is becoming ever more apparent and critical that healthcare should shift focus towards developing preventative strategies for monitoring and maintaining health as well as therapies that can directly address the various aging processes to delay or prevent the onset of age-related diseases.

One of the most important ways in which science can achieve this is through the development of effective ways to measure how someone is aging. This involves developing accurate aging biomarkers that can determine biological age, the true measure of how much someone has aged; this is distinct from chronological age, which is simply how many years a person has lived.

Using chronological age is not really very useful as it gives a poor indication of how fast or slow someone is aging, and it is not an accurate way to determine an individualโ€™s risk factor for developing various age-related diseases. This is quite simply because everyone ages at different speeds, and even the organs and tissues in a single person can age at different rates. While everyone ages and that aging is driven by the same aging processes, the speed at which these different processes occur can vary considerably between people.

In fact, a study this year showed how this varied aging rate across multiple tissues and organs means that people all have unique aging profiles, known as ageotypes [1]. The results of their study and the biomarkers they used show how your ageotype shows how you age.

Essentially, when it comes to developing aging biomarkers that are clinically relevant, the challenge has always been in determining what exactly to measure in order to give the most accurate picture of a personโ€™s biological age.

Today, we want to draw your attention to a new review published in the journal Science. it includes researchers Joรฃo Pedrode Magalhรฃes, Vadim N. Gladyshev, and Alex Zhavoronkov, names our regular readers are no doubt familiar with [2]. The review takes an in-depth look at the current generation of “aging clocks”, biomarker panels that measure the gene expression profiles of mice and people to calculate their biological ages. The review also considers the limitations of these clocks along with the future development of biomarkers, including the ever-increasing use of deep learning.


A link to a supplement website called NOVOS.

The aging process results in multiple traceable footprints, which can be quantified and used to estimate an organism’s age. Examples of such aging biomarkers include epigenetic changes, telomere attrition, and alterations in gene expression and metabolite concentrations. More than a dozen aging clocks use molecular features to predict an organism’s age, each of them utilizing different data types and training procedures. Here, we offer a detailed comparison of existing mouse and human aging clocks, discuss their technological limitations and the underlying machine learning algorithms. We also discuss promising future directions of research in biohorology โ€” the science of measuring the passage of time in living systems. Overall, we expect deep learning, deep neural networks and generative approaches to be the next power tools in this timely and actively developing field.


The more high-quality and reliable aging biomarkers we have access to, the better, especially given that a number of therapies that target aging are now near or even in human trials. The need for accurate ways to measure biological aging and its potential reversal via therapies has never been more critical.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if itโ€™s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Nobel Prize in Medicine Goes to Two mRNA Vaccine Researchers

Katalin Karikรณ and Drew Weissman received this yearโ€™s Nobel Prize in Physiology or Medicine for a groundbreaking discovery that facilitated...

NMN Reduces Systolic Blood Pressure in Clinical Trial

Combining human clinical trial research, cellular analysis, and mouse studies, researchers publishing in the Nature journal Signal Transduction and Targeted...

Rejuvenation Roundup September 2023

On some corners of the Internet, "Spooktober", effectively a month-long Halloween, has just begun. Here at Lifespan.io, though, we talk...

Longevity and DeSci Recap โ€“ September 2023

Welcome back to the latest edition of the Longevity and DeSci Recap. Here, youโ€™ll discover the latest interviews, insights, and...


[1] Sara Ahadi, Wenyu Zhou, Sophia Miryam Schรผssler-Fiorenza Rose, M. Reza Sailani, Kรฉvin Contrepois, Monika Avina, Melanie Ashland, Anne Brunet & Michael Snyder. Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nature Medicine, 2020 DOI:

[2] Galkin, F., Mamoshina, P., Aliper, A., de Magalhรฃes, J. P., Gladyshev, V. N., & Zhavoronkov, A. (2020). Biohorology and biomarkers of aging: current state-of-the-art, challenges and opportunities. Ageing Research Reviews, 101050.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri โ€“ Google AR and Dinorah Delfin โ€“ Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.